U.S. markets close in 6 hours 26 minutes
  • S&P 500

    4,560.41
    +27.65 (+0.61%)
     
  • Dow 30

    35,201.04
    +172.39 (+0.49%)
     
  • Nasdaq

    14,510.35
    +170.09 (+1.19%)
     
  • Russell 2000

    2,062.78
    -33.44 (-1.60%)
     
  • Crude Oil

    86.80
    -0.16 (-0.18%)
     
  • Gold

    1,845.70
    +2.50 (+0.14%)
     
  • Silver

    24.55
    +0.31 (+1.30%)
     
  • EUR/USD

    1.1351
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    1.8240
    -0.0030 (-0.16%)
     
  • GBP/USD

    1.3638
    +0.0026 (+0.19%)
     
  • USD/JPY

    114.1360
    -0.2170 (-0.19%)
     
  • BTC-USD

    42,491.77
    +250.05 (+0.59%)
     
  • CMC Crypto 200

    1,010.49
    +15.23 (+1.53%)
     
  • FTSE 100

    7,568.92
    -20.74 (-0.27%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

Investors See No Limit For Inotek Pharmaceuticals

Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.

Inotek Pharmaceuticals Corp (NASDAQ: ITEK) shares were trading sharply higher by $9.30 (190 percent) at $14.60 in Thursday's session. The catalyst for the rally is the announcement of a positive end-of-phase 2 meeting with FDA and Phase 4 development for Trabodenoson, a novel treatment for glaucoma.

In addition, Cowen hopped on the bandwagon and raised its price target all the way to $40.

After a sharply higher open ($8.32 vs. Wednesday's close of $5.23), it retreated to $7.66 before heading into the stratosphere. So far, the rally has taken the issue beyond its former all-time high ($6.20) to $16.75 before falling back under $15.

The rally is taking place on monster volume. So far, 41.1 million shares compared to its 20-day average of a meager 2 million shares as the close approaches.

See more from Benzinga

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.